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Executive summary 
Background 
The European Centre for Disease Prevention and Control (ECDC) has a responsibility to identify, assess and 
communicate current and emerging threats to human health from communicable diseases. Surveillance data 
follow trends in time and indicate health problems resulting from particular diseases, but are subject to under-
reporting and do not account for disease severity. To increase insight into the impact of communicable diseases 
on population health in Europe and to support health policy-making, in 2008 ECDC initiated a call to develop a 
methodology for measuring the current and future burden of communicable diseases in the European Union 
Member States and European Economic Area (EEA)/European Free Trade Association (EFTA) countries. The 
result was the current and future Burden of Communicable Disease (BCoDE) project. 
The current protocol is the output of Work Package 1 of the BCoDE project. Choices concerning the methodology 
of future disease burden estimates were taken on the basis of literature reviews, data reviews and the results of 
workshops/expert meetings. These are summarised in the current protocol. 
Objectives 
The primary objective of the BCoDE project is to generate evidence-based, valid and comparable estimates of 
the burden of communicable diseases and related conditions on society in EU Member States and EEA/EFTA 
countries. The aim of Work Package 1 was to assess and define the methodology used to generate these 
estimates. In defining the tools for the generation of estimates one rationale was to ensure comparability with 
earlier burden estimates published by WHO. 
Methods 
The communicable diseases for which disease burden will be calculated were selected on the basis of a 
consensus reached by the ad hoc Advisory Forum working group, resulting in a predefined list of 
inclusion/exclusion criteria. The disease burden of the selected diseases will be calculated for all Member States 
of the European Union and EEA/EFTA countries. The disease burden will be estimated using DALYs (Disability-
Adjusted Life Year), a health gap measure representing years of life lost (YLL) due to premature death and 
number of life years lost due to disability (YLD). To better represent communicable diseases and their associated 
sequelae, we will use the pathogen-based DALY approach which links sequelae to their cause of infection 
(pathogen). Disease burden caused by sequelae is thereby attributed to incident infections. This can be done by 
taking an incidence and pathogen-based approach, where the incidence of infections is linked to all possible 
sequelae through an outcome tree or disease progression model. The outcome trees used in this study are based 
on literature reviews and have been analysed by ECDC’s Disease-Specific Programmes (DSP). Health states are 
considered part of the outcome tree if there is evidence of a causal relationship between infection and the health 
state.  
In the disease burden calculations YLL will be estimated using the Standard Expected Years of Life Lost (SEYLL) 
based on the highest observed life expectancy, which is that of the Japanese population. A European life 
expectancy will be used as an alternative. Severity weights (i.e. disability weights) for non-fatal health outcomes 
were obtained from the WHO Global Burden of Disease (GBD) study and will be updated when new weights 
become available. In conditions for which no weights exist, weights will be adapted from existing GBD severity 
weights for similar conditions. Time discounting and age-weighting will not be applied in the base case analysis, 
but it will be possible to do so if necessary. Reported incidences will be averaged over a three-year period (2005-
2007) to ensure the stability of estimates. The resulting averages will be checked for representativeness in 
relation to longer reporting periods and, if necessary, the time span for the averaging will be pathogen-based. 
Data on mortality will be used from both national sources and EUROSTAT with correction for under-reporting 
where necessary. Attributable fractions and modelling will be used for fatal cases of disease with multiple causes.  
Surveillance data, hospitalisation data, primary care data and disease-specific registration databases will be used 
to estimate incidences of the various non-fatal health outcomes. However, these data sources may only 
represent part of the true incidence due to under-reporting and under-ascertainment. Therefore, methods will be 
applied to correct for under-reporting. Attributable fractions and modelling will also be used for non-fatal health 
states with multiple causes. The duration of health states will be based on national estimates, where available. 
Disease burden models will be implemented in Excel using @Risk (an add-in to Excel) in order to explore 
uncertainty. The outcomes of the model are disease burden estimates associated with a specific infectious 
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disease and its related sequelae in a particular country. The estimates will be presented as DALYs/YLL/YLD per 
year per country, DALYs per 100 000 population per year and DALYs per year per infected case. Point estimates 
(means) of these quantities, together with measurements of their uncertainty (e.g. 95% credible intervals) will 
be presented and discussed and, where necessary, scenario analysis conducted. The current modelling approach 
assumes steady-state and is therefore not suitable for predicting disease burden into the future.  
Perspective 
Using the above approaches it is possible to obtain disease burden estimates that enable comparison among 
communicable diseases and an assessment of their relative impact on public health. Furthermore, the estimates 
obtained enable comparison with other factors affecting public health, both within and among countries. Thus,  
the burden of disease estimates will make it possible to prioritise future monitoring and intervention efforts for 
communicable diseases. The methodology described in this protocol represents a first step in the development of 
methods to estimate disease burdens for communicable diseases. Future work will extend and improve the 
methods described by taking temporal dynamics and demographic developments into account. Therefore this 
protocol should be seen as a working document that will be subject to change as the project progresses in future 
work packages. 
Purpose 
Why the BCoDE project? 
The European Centre for Disease Prevention and Control (ECDC) has a responsibility to identify, assess and 
communicate current and emerging threats to human health from communicable diseases.1 As part of its efforts 
to meet this responsibility, ECDC produces the Annual Epidemiological Report on Communicable Diseases in 
Europe.2
In order to meet the above-mentioned responsibility, in 2008 ECDC initiated a request for proposals to develop a 
methodology to measure the current and future burden of communicable diseases in the EU Member States and 
EEA/EFTA countries. This resulted in the Burden of Communicable Disease in Europe (BCoDE) project.  
 The data reported describes trends and, although it can be used to indicate health problems due to 
particular diseases, it is not suitable for a comprehensive assessment of disease burden. In order to make such 
an assessment information is required on the severity of disease, including morbidity due to sequelae and 
disease-related mortality.  
The current methodology protocol was developed in Work Package 1 and describes the methodology to be 
applied when measuring the burden of communicable disease in EU Member States and EEA/EFTA countries 
under the BCoDE project.  
Steps towards the methodology protocol 
A metric for communicable diseases  
Various metrics exist for capturing and weighing the specific symptoms, severities, chronic sequelae and 
incidence of morbidity and mortality associated with each hazard as one single integrated unit. Both monetary 
and non-monetary integrated measures may be applied to value health effects. Given the numerous method 
options available, an investigation was necessary to find the one most suitable for describing burden of 
communicable disease. Furthermore, it was necessary to determine whether the chosen method would allow for 
comparison among the various communicable diseases in different countries, and possibly also with other chronic 
diseases. 
 
 
                                                                    
1 Decision No 2119/98/EC of the European Parliament and of the Council of 24 September 1998 setting up a network for the 
epidemiological surveillance and control of communicable diseases in the Community 
2 http://ecdc.europa.eu/en/publications/Publications/1011_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf 
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Metric selection based on literature workshops and expert meetings 
In order to carry out these necessary steps and to obtain the most appropriate method, a literature review was 
performed, focusing on methodological and modelling issues related to both the measurement of burden of 
disease in general, and that of communicable disease in particular. The findings were discussed at workshops 
organised in close collaboration with ECDC. Participants included all BCoDE consortium members and other 
experts, with expertise ranging from epidemiology, health economics and demography to public health policy-
making. The conclusions of the review and discussion process form the basis for the methodology chosen for 
calculating the first disease burden estimates under the BCoDE project. The methodology is set out in this 
protocol.  
Further information necessary for disease burden calculations 
In addition to choosing the methods for calculating disease burden from a variety of data sources, we collected 
information concerning data availability, disability weights and parameters describing disease progression. This 
information is necessary for the actual disease burden estimates. A literature review was conducted in order to 
define the potential health states for both acute illness and sequelae based on association and causal links. An 
inventory was compiled of the data sources available in the EU Member States and EEA/EFTA countries and a 
scoring exercise was carried out to analyse the strengths and weaknesses of these (e.g. notification data, 
hospitalisation data, surveillance data). Given that most of the data are far from complete, a literature review 
was conducted to define potential methods for correcting under-reporting, over-reporting and under-
ascertainment. 
Objective 
The primary objective of Work Package 1 was the development of a methodology to generate evidence-based, 
valid and comparable estimates of the burden of communicable diseases and related conditions on society within 
EU Member States and EEA/EFTA countries. 
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Methodology for the BCoDE project 
Selection of pathogens and countries 
Countries considered 
Disease burden calculations of the selected pathogens are planned for all European Union Member States and 
EEA/EFTA countries.  
Selection of pathogens 
 
The aim of the BCoDE project is to estimate the burden of disease for as many as possible of the 49 diseases 
listed in Decision 2119/98/EC. However, a more formal and systematic procedure was deemed necessary in 
order to obtain a final, validated list of diseases. ECDC therefore developed an explicit procedure to identify the 
final list of pathogens/diseases to be included in the study.  
A list of inclusion/exclusion criteria was submitted to an ad-hoc ECDC Advisory Forum working group for scoring. 
For methods and the final list of diseases included in the BCoDE project, see Annex 1.  
Methodology choices for calculating disease burden 
The methodology choices 
The term “burden of disease” (BoD) is used to quantify the impact of a disease on a geographical region or 
population. However, since diseases affect patients and populations in various ways, a multitude of indicators 
can be used to quantify the BoD (e.g. incidence estimates, prevalence estimates, Disability-Adjusted Life Years 
[DALY]). Given the aim of the BCoDE project, the rationale for choosing a BoD indicator was that it should 
capture and weigh the distinct symptoms, severities, chronic sequelae and incidence of morbidity and mortality 
associated with each hazard in a single metric. A further rationale was that this integrated measure should allow 
comparison between communicable diseases within and among countries and, where possible, comparison with 
burden related to other conditions (not caused by communicable diseases). Finally, the chosen indicator would 
have to take into consideration specific issues related to communicable diseases and be sufficiently flexible to 
allow future development towards a methodology that can account for the dynamic nature of infectious disease 
epidemiology and the impact of intervention.  
Integrated measures 
 
Both monetary and non-monetary integrated measures have been developed to value health effects. These 
measures have in common that they integrate the health state associated with a particular disease in several 
countries into a single metric. 
In the BCoDE project the focus is on the burden in terms of morbidity and mortality and not economic evaluation 
or assessment. For this reason non-monetary integrated measures will be used here which can, at a later stage, 
provide the basis for an economic analysis if desired. 
DALY and QALY: the most prominent non-monetary integrated measures 
 
Among the various non-monetary integrated generic measures (i.e. measures that can be used across different 
diseases) in the scientific literature, Quality-Adjusted Life Years (QALY) and Disability-Adjusted Live Years (DALY) 
are the most prominent and they are also the most appropriate measures for disease burden calculations of 
communicable diseases. 
This project will apply the DALY methodology to measure health gaps. 
In this project, a non-monetary integrated measure for health valuation will be used which can act as the basis 
for economic evaluations at a later stage. 
 
Inclusion/exclusion criteria for the selection of pathogens were submitted to an ECDC ad hoc Advisory Forum 
working group and a final list of pathogens was agreed upon. 
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The QALY approach assigns a quality-of-life index (i.e. a utility) to each health state, reflecting the desirability of 
that health state. Health states are usually valued between 0 (for death) and 1 (for perfect health). The QALY 
loss associated with an adverse health state is measured as the difference between QALYs with and without the 
condition. An overview of the different features specific to the QALY methodology is given in Table 1. QALYs are 
widely used in economic evaluation. The utility weights used in these studies are generated either directly or 
indirectly. If elicited directly, the preferences of either the patient, the general public or the physician are 
obtained using one of the following techniques: Standard Gamble (SG), Time Trade-Off (TTO), Person Trade-Off 
(PTO) or Visual Analogue Scale (VAS) (see Box 1). However, the choice of preferences − the values of patients, 
physicians or the general public − may influence the results. Some studies indicate that patients who have 
experienced the disease and partially adapted to it tend to place higher values on dysfunctional health states 
than the general population. This discrepancy becomes even more marked when patients value their own health 
state. The main factors contributing to the differences observed are poor descriptions of health states (for the 
general population), use of different internal standards, response shift and adaptation. In the case of indirect 
utility assessment, the dimensions of specific health states are rated on the basis of validated questionnaires 
(index instruments), such as EQ-5D, SF-6D, HUI and 15D. They are then validated using general population 
preferences. The algorithm for assigning values to each health state is obtained from a sample of the general 
adult population using one of the valuation techniques described in Box 1 (e.g. SG, TTO and VAS). However, 
these different instruments estimate different utility weights for the same health state, making it hard to 
compare them. 
The DALY belongs to the family of health gap measures that calculate health losses based on the gap between 
the current health status and some ideal health goal that is defined arbitrarily. Thus, one DALY represents a loss 
of one year of life lived in perfect health. In the DALY methodology the severity of disease states is quantified by 
the use of disability weights that place a value on disease states between 0 (perfect health) and 1 (death). An 
overview of the different features describing the DALY methodology is given in Table 1. The DALY methodology 
was jointly developed by the World Bank, the World Health Organization (WHO) and the Harvard School of Public 
Health in the late 1980s for the Global Burden of Disease (GBD) study. The main idea behind the framework of 
the DALY was to incorporate both mortality and non-fatal health outcomes into a single measurement unit. This 
unit was to provide a comprehensive and comparable tool for describing the burden of disease and conditions in 
all countries worldwide. To meet this objective, the basic assumption was that similar events would be treated 
equally in all populations to ensure comparability. For example, the loss of a finger in Zimbabwe and the loss of a 
finger in Turkey should contribute equally to burden of disease. The original GBD DALY measure, its components 
and methodology were debated in the literature and in various international forums. The methodology has now 
been established as the gold standard and is applied in various national and sub-national burden of disease 
studies (see Table 1 for examples). The GBD project is ongoing and some major revisions have been made to 
the methodology. In the first GBD study, Murray and Lopez (1,2) used the PTO method (see below) to determine 
disability weights for more than 100 diseases and related sequelae. The weights were used in subsequent GBD 
studies in 2000, 2002 and 2004. For a future update of the GBD study WHO is currently revising the disability 
weights using novel elicitation methods. The main objective of the revision is to improve the methodology and to 
present a transparent, rigorous and standardised approach for generating disability weights. In addition to the 
GBD severity weights there are also some national severity weights available. 
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Table 1. Guidance checklist: An overview of DALYs and QALYs 
Disability-Adjusted Life Year (DALY) as developed by WHO Quality Adjusted Life Years (QALY) 
Summary measure of population health type 
Health gap. 
Summary measure of population health type 
Health expectancy 
Unit of measurement 
• Years of life lost in a population due to premature death and 
disability, referring to an arbitrarily predefined health goal 
• Sum of Standard Expected Years of Life Lost (SEYLL) and Years 
Lost due to Disability (YLD) 
Unit of measurement 
• Is a product of survival time and quality of time 
• QALYs are generally expressed as QALYs obtained by 
comparing two populations 
Health dimension under consideration 
• Disability− i.e. loss of functional capacity 
Health dimension under consideration 
• Health-related quality of life associated with certain health 
states 
Information on mortality 
• Yes - SEYLL 
 
Information on mortality 
• Yes - standardised life expectancy of the population under 
study (i.e. general population; drug-users, etc.) 
Information on non-fatal health outcomes? 
• Yes - YLD 
Information on non-fatal health outcomes? 
• Yes - through quality of life associated with non-fatal health 
outcomes 
Disease-specific approach? 
• Yes - e.g. conditions can be linked to an ICD classification 
Disease-specific approach? 
• No - approach based on health state descriptions which 
might be indirectly linked into a disease-specific approach 
Characteristics of the measurement 
• DALYs developed for assessments in the Global Burden of 
Disease study 
• Internally consistent set of DALY estimates 
• Comparability of DALY estimates between populations and 
diseases and over time 
• Comprehensive set of disease and injury causes, in principle 
nothing is left out 
• Includes 108 specific disease and injury conditions, classified in 
a tree structure with four levels of disaggregation. First level 
comprises Group I, II, and III conditions: Communicable 
diseases, non-communicable diseases and injuries 
• Like events are treated equally − i.e. like events contribute to 
the same number of DALYs, irrespective of the individual’s 
environment 
• Individual characteristics are restricted to age and sex 
Characteristics of the measurement 
• Developed by economists, decision scientists and 
psychologists 
• Preference-based measure 
• Intended use for evaluation and intervention planning 
• Comparison of interventions 
• Primary use for cost-utility analysis 
• Applies cost-utility ratio which describes the incremental 
price of obtaining a unit of health effect 
• Utilities may differ from country to country/region to region 
• Utilities may be derived directly, or indirectly 
Data requirements 
• Mortality data, life table, population data, causes of death 
• Incidence, disability weights (currently only available for the 
Netherlands, Estonia and WHO), duration of disease 
Data requirements 
• Expected duration of stages; time-to-event or event 
probabilities and utility weights; (all factors of a natural 
history model) 
Value choices 
• Age weighting 
• Sex-specific weights 
• Time discounting 
• Disability weights 
• Health goal 
Value choices 
• “If... then” applied, also age weighting 
• “If... then” applied, sex-specific weights 
• Time discounting 
• Utility weights 
Example used in: 
• WHO Global Burden of Disease studies 
• More than 20 national burden of disease studies (e.g. USA, 
Mexico, Chile, Turkey, Brazil, Australia, Singapore, Iran, Peru, 
Netherlands, South Africa, Zimbabwe)  
• Several local burden of disease analyses 
• Disease and risk factor-specific assessments (e.g. chikungunya, 
dengue, food-borne pathogens, lead, vitamin A, stroke, 
hepatitis C, climate change) 
Example used in: 
• Routinely used in economic evaluation of medical care, 
technology and public health interventions in Europe and 
elsewhere 
Limitations 
• No co-morbidity 
• Comparative risk assessment restricts the attribution of DALYs 
to single risk factors. 
Limitations 
• Value sets derived from different countries are not 
comparable and cannot be used for cross-national 
comparisons  
• Resource and time intensive. 
Both summary measures are suitable for quantifying the burden of communicable diseases and make it possible 
to compare the burdens of different communicable diseases within and between countries. Furthermore, DALYs 
and QALYs allow disease-specific weighting of health consequences. Although QALYs are commonly used in 
economic evaluations, the utility weights  in these studies come from different sources employing various 
instruments and techniques. As economic evaluations are mostly conducted at the national level, the utility 
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weights usually represent national estimates, sometimes making a comparison between different QALY-based 
studies difficult. It would be difficult or even impossible to compile a list of utility weights based on the same 
underlying assumptions and using the same techniques for all health states related to the communicable 
diseases under study in the BCoDE project. The advantage of using DALYs is therefore that disability weights 
obtained using the same methods and assumptions are available from the GBD study for a large number of 
communicable diseases and their sequelae. Using them will to some extent ensure comparability with the GBD 
estimates. Therefore, at this stage of the BCoDE project, the DALY methodology is the most suitable for disease 
burden calculations. 
Disability-Adjusted Life Years 
The DALY is a health gap measure that extends the concept of potential years of life lost due to premature death 
to include equivalent years of “healthy” life lost in states of less than full health, or in more general  terms 
disability. One DALY is one lost year of healthy life (WHO definition). The DALY methodology has been described 
by Murray et al (1-2) in the Global Burden of Disease (GBD) project using the following equation: 
 DALY = YLL + YLD. 
YLL is the number of years of life lost due to premature death and YLD is the number of years of life lost due to 
disability. The number of years lost due to disability are computed by weighting each remaining life year with a 
factor between 0 (perfect health) and 1 (death) for an incident disability. The YLL due to a specific disease in a 
particular population is calculated by totalling  the number of all fatal cases due to the health outcomes of a 
specific disease, each case multiplied by the remaining individual life expectancy at the age of death. More 
specifically, let ni (a) be the number of incident cases at age a of a disease with health states i =1,...,k, where k 
is the number of different health outcomes due to the disease, and di (a) the number of deaths at age a due to 
health outcome i. If E (a) is the remaining life expectancy at age a, and amax the maximum age, then: 
 
The YLD is calculated as the product of the duration of the illness and the disability weight of a specific disease 
outcome accumulated over the number of incident cases for all health outcomes. If the duration of health 
outcome i  is indicated as Di  and its disability weight as wi, then: 
 
E (a) and Di have time as a unit, all other quantities are dimensionless numbers. Age is discretised into (amax +1) 
yearly age classes.  
Pathogen-based DALY approach 
Different methods have been developed for computing DALYs. DALY computations depend on the underlying 
assumptions as to how sequelae are linked to one another and to their infectious causes, how transitions 
between disease states are defined and quantified and whether time since infection is explicitly considered when 
describing disease progression. In the DALY approach applied in the GBD project (1-2) (3-4) disease burdens 
were estimated by totalling years of life lost (YLL) due to premature deaths and years of life lost due to disability 
(YLD) from incident disease cases. For some diseases long-term sequelae were included in the estimates, but 
many long-term sequelae were treated as separate disease entities with diverse aetiology. 
For communicable diseases, the burden of disease associated with long-term sequelae is in some cases higher 
than the burden of disease associated with acute illness (e.g. STEC O157, Campylobacter). In order to attribute 
all the health consequences of an infection to the infection event, and therefore estimate the full burden caused 
by the infection, sequelae have to be considered as consequences of the infection. This is done by adopting an 
approach known as the pathogen-based DALY approach, as suggested by van Lier et al. (5). This approach, 
which relates all sequelae to their infectious causes by means of an outcome tree, will be used in the BCoDE 
study. 
 
 
 
 
Current and future Burden of Communicable Diseases in the EU and EEA/EFTA  TECHNICAL REPORT 
 
12 
 
 
 
Relating sequelae to their infectious causes by means of an outcome tree involves the description of all health 
outcomes and their possible transitions in a flow chart. An individual enters the flow chart by infection and leaves 
by recovery or death. All intermediary states contribute to the disease burden. In contrast to full disease 
progression models that describe events after infection in relation to the time since infection, outcome trees do 
not take the time element into account. In a sense, an outcome tree attributes the complete disease burden to 
one point in time − the time at which infection occurs. Therefore, the outcome tree method is not suitable for 
projecting future burden estimates (Annex 2). With long-term sequelae projected to the present and treated as 
acute events, the crucial underlying assumptions of this method are that demographic and disease dynamics 
remain a steady state (see Figure 1). Although from a methodological point of view a full disease progression 
model is preferable, we realise that this cannot be achieved within the scope of this project. We have therefore 
chosen to base our estimates on outcome trees with the possibility of extending our estimates to full disease 
progression models in the future. The “pathogen-based DALY approach”, as used in the pilot study by van Lier et 
al. (5) will be the first method implemented in the BCoDE project. Extensions of the method may be considered 
at a later stage. 
Figure 1. Graphical illustration of the pathogen-based DALY approach 
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Incidence approach and pathogen-based approach 
 
Pathogen-based approach 
Disease burden estimates can either be assigned to an outcome − i.e. clinically defined categories of diseases 
irrespective of their cause, or to a cause − i.e. a pathogen. For communicable diseases we considered it 
important to assign the disease burden to a particular pathogen, as this makes it possible to assess the disease 
burden of both acute illness and related sequelae/complications caused by a particular pathogen. The pathogen-
based approach will therefore be applied in the BCoDE project. 
Incidence approach 
Disease burden calculations can be based on incidence of infections or on incidence or prevalence of health 
outcomes. Premature death can also be viewed as a health outcome. The difference is that incidence of infection 
is measured per unit of time whereas the prevalence is a number or proportion. An incidence approach implies 
that all health outcomes, including their durations and weights, will be attributed to one point in time, when the 
infectious event takes place. From a practical point of view, there is a tendency to use the data notified in 
surveillance systems as a baseline incidence. Having decided to apply the pathogen-based approach, for which 
the full array of sequelae related to communicable diseases are assigned to the pathogen, the incidence 
approach is the most appropriate method and will therefore be applied in the BCoDE project. However, this does 
not preclude the use of prevalence data to estimate the number of chronic infections or other sequelae arising 
from an infection. For example, prevalence data will be used to validate results from incidence-based estimates if 
information on attributable fractions by cause is available for an outcome.  
Outcome trees 
 
Possible health outcomes of infectious diseases range from acute self-limited disease to chronic disabilities or 
even death. In order to assess the burden of disease for the selected pathogens, we need to define the different 
health outcomes following infection by a particular infectious agent. These disease outcomes can be described in 
the form of an outcome tree (see Figure 2). An outcome tree gives a qualitative representation of the disease 
progression over time by ordering all relevant health states following infection and illustrating their conditional 
dependency.  
The construction of outcome trees implies making choices on the outcomes to include or exclude from the 
analysis. The first inclusion/exclusion criterion would be the strength of evidence for a causal relationship. 
According to Mitchell et al (6) examples are: 1) Sufficient evidence of a causal relationship 2) Sufficient evidence 
of an association 3) Limited or suggested evidence of an association 4) Inadequate or insufficient evidence to 
determine whether an association exists and 5) Limited or suggestive evidence of no association. 
Outcomes that contribute little to the final result (because they are extremely rare and/or low-severity) could be 
excluded. Furthermore, the construction of the outcome tree is usually also guided in part by data availability. As 
scientific knowledge grows in the future, new outcomes may be causally linked to particular pathogens and the 
outcome tree may need to be updated, possibly increasing the burden of disease attributable to a particular 
pathogen. 
Sequelae will be linked to their causative pathogen by means of outcome trees. In this way burdens caused by 
sequelae will be linked to their causes. For validation purposes, attributable fractions will be used to interpret 
prevalence data for outcomes with competing causes so that overall burdens are not overestimated/counted 
twice. Outcome trees are based on the Bradford-Hills criteria for causality and on recommendations and 
validation from ECDC Disease-Specific Programmes. 
The basis for burden of disease estimates will be incidence estimates of infection by pathogen. 
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Figure 2. An outcome tree describes all outcomes caused by an infection 
 
An outcome tree was drafted for each of the selected pathogens, including all outcomes with sufficient evidence 
of a causal relationship or an association (first two categories). These outcome trees were then assessed by the 
Disease-Specific Programmes (DSPs) at ECDC and finalised, incorporating modifications based on the experts’ 
recommendations.  
Value choices 
Applying the DALY methodology involves decisions which should reflect relevant value choices, as described 
below. 
Life expectancy 
 
Estimating YLLs requires the definition of a population health goal. To a certain degree the decision for a health 
goal is arbitrary and depends on the objectives of a burden of disease study. The health goal, defined in terms of 
healthy life expectancy, represents a point of reference. A burden estimate is therefore always a measure of a 
population’s deviation from that reference point. A health goal may represent a potential limit to healthy lifespan 
or a given life-expectancy in ideal health. YLLs are then measured as the difference in years between the age-
dependent health goal and the age of death.  
As in the GBD study, we will use the most recent Standard Expected Years of Life Lost (SEYLL), a life expectancy 
distribution based on that of the Japanese population. In Japan, life expectancy at birth is the highest worldwide 
for both men and women. Alternatively we will consider a European life expectancy distribution, as suggested by  
ECDC’s internal management. The Icelandic life expectancy distribution for males and the French life expectancy 
distribution for females are the highest observed in the European Union and EEA/EFTA countries (Eurostat)3
 
                                                                    
3
http://epp.eurostat.ec.europa.eu/statistics_explained/index.php?title=File:Life_expectancy_at_birth(years).PNG&filetimestamp
=20090430100004 
.  
Standard Expected Years of Life Lost (SEYLL) will be used as the baseline. Our approach will be modular to 
allow replacement of one life expectancy distribution with another. 
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However, since the mortality burden of communicable diseases is relatively low, using a common life expectancy 
for different European countries might overestimate the relative impact of communicable diseases in countries 
with a lower life expectancy due to chronic causes. For these countries, comparison with burden estimates based 
on national life expectancies can be useful to assess the magnitude of overestimation. In this project, we will 
follow a modular approach that allows the replacement of one life expectancy distribution by another. This will 
also enable scenario analysis with respect to health goals. 
Disability weighting 
 
Disability weighting means that each outcome of a disease is assigned a value on a scale from 0 (perfect health) 
to 1 (death). These values may be dependent on the population in which they are measured, reflecting the 
norms and life conditions of that society. Ideally, the disability weights used to estimate a burden should reflect 
the values measured in the populations studied. However, disability weights are not usually available at the 
national level. Disability weights can be determined using different methods. Ideally, the weights reflect the 
values for the general population (as opposed to specific population groups) used for policy-making purposes at 
the national or international level. Weights based on elicitation panels made up of lay persons are increasingly 
becoming available, whereas in the past work was based on the results of expert panels (e.g. medical 
professionals). Values from patients who actually suffer from a disease are not considered informative for the 
purposes of estimating burdens, because patients’ coping behaviour tends to influence the valuation process.  
Different valuation techniques (see Box 1) are available for panel elicitation, including the Standard Gamble (SG), 
Time Trade-Off (TTO), Person Trade-Off (PTO) and Visual Analogue Scale (VAS). All methods give different 
results (usually VAS > TTO > PTO > SG), but they are correlated. The SG and VAS are sometimes problematic 
because they are only sensitive to severe disease (SG) or very sensitive to mild diseases (VAS) and this may lead 
to compression at either end of the scale. For this reason the TTO and PTO methods are often preferred. 
The international transferability of disability weights is also a matter of concern. A study in western Europe 
concluded that there was “a reasonably high level of agreement on disability weights in western European 
countries with the VAS and TTO methods, but a lower level of agreement with the PTO method” (7). However, a 
recent study concluded that “Meaningful differences exist in directly elicited TTO valuations of EQ-5D health 
states between the United States and United Kingdom general populations” (8). Hence, severity weights should 
ideally be based on specific elicitations for the population under investigation, but this may be very difficult for 
the EU or even for a specific country. Given that the most comprehensive set of severity weights has been 
generated by WHO , and alternative weights are only available sporadically for specific countries (e.g. the 
Netherlands) or health states, the BCoDE project will use the internationally available disability weights from the 
GBD study. This enables us to compare our burden estimates with those obtained by WHO (assuming that we 
also use the same life expectancy distribution). WHO is currently updating its disability weights using a novel 
elicitation method to include health states that were previously not valued. By taking a modular approach to the 
computing of burden estimates we will be able to replace the present disability weights by new ones as they 
become available.  
WHO-generated disability weights will be used. For health states where weights are not available weights will 
be used from health conditions of similar severity. As updated WHO weights become available these will be 
used as the gold standard. 
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As our outcome trees for the selected pathogens also include health outcomes for which WHO has not yet 
defined disability weights, we will have to “adapt” the disability weights from the existing list. This will be done 
by classifying both WHO existing health states and the new outcomes in accordance with the EQ-5D classification 
system. Each health state/outcome will be classified using five dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression, and three existing levels per dimension. Altogether there will be 243 
possible health states. Based on this “EQ-5D state” we will then match new outcomes with existing health states 
against the same “EQ-5D state”. If there is more than one comparable health state we will determine which is 
the closest in terms of symptoms and preferences, based on the expert opinion of physicians. 
Box 1. The different valuation techniques 
Standard Gamble (SG) 
The SG method is the classic method for determining individuals’ preferences, incorporating uncertainty as an 
element of the decision-making process (9). Using the SG technique, a scenario of a particular health state is 
presented to the respondents. They have to choose either to live with the presented health state for the rest of 
their lives or to receive some form of intervention, with an arbitrary risk probability of dying and another of 
getting well and living out their lives in optimal health. If the respondents decide to live with the presented 
health state, the gamble will be made more attractive by increasing the chance of getting well again. If they 
choose the gamble, the chance of getting well will be reduced. Having completed the first step, the 
respondents are repeatedly asked to select one of these two choices in different scenarios. After reaching a 
point of indifference, the respondents are unable to make further choices between the two possibilities. At this 
point it is possible to determine a utility scale number. This number determines the health scenario in the first 
alternative in relation to the health scenario in the second alternative. Thus, it is possible to determine sets of 
utility weights for different health states (10-12). 
Rating or Visual Analogue Scales (RAS, VAS) 
An alternative method to determine severity values for health states is to ask an individual to indicate the 
relative desirability of a state on a scale between 0 and 1, with 0 representing death and 1 a state equivalent to 
full health. Analogue rating scales are widely used to generate health state preferences. For example, the RAS 
and VAS technique has been used in the Quality of Well-Being Scale (QWB) and the EuroQol (EQ-5D) (10). 
Time Trade-Off (TTO) 
Another technique for assessing weights for different health states is the TTO method developed by Torrance 
et al (13). In this exercise respondents are asked whether they would like to spend the rest of their lives in a 
described health state, or to live a shorter life in a state of excellent health. As with the SG method, the 
respondents can choose between these two scenarios. If the respondents decide to live with the inferior health 
state for longer, the fraction of time will be prolonged in the alternative scenario. If the respondents opt to live 
a shorter life in excellent health the fraction of time will be reduced. As with the SG method, the continuous 
use of the TTO exercise leads to a point of indifference at which the remaining lifetime in the inferior health 
state becomes equivalent to less time in an excellent health state. This point of indifference is then used in an 
equation to calculate severity weights for different health states (10). 
Person Trade-Off (PTO) 
The preference values can also be determined using two variants of the PTO method. In the first exercise, as 
performed by Murray et al in the first Global Burden of Disease study (2-3), the respondents were asked to 
trade off the life extension of people at different health stages. They were first asked to trade off the life 
extension of healthy individuals and individuals in a given health state that was assumed to be less than 
excellent. In a second PTO exercise, the respondents were asked to decide between increasing the quality of 
life of people with inferior health or extending the life of people in excellent health for one year. The 
respondents were then asked to share their preference weights for the first and second PTO exercise in private. 
Afterwards all respondents were shown the results of the other participants’ valuations and given the chance to 
discuss why they had chosen their preferences. After the discussion the respondents were able to revise their 
weights (2-3). A further form of the PTO method has been developed in the European context. This method 
involves finding a trade-off between preventing incident cases of a rapidly developing fatal disease and 
preventing incident cases of a chronic disease. Respondents are asked how many cases of chronic disease 
should be avoided before they can be indifferent to 100 rapidly developing fatal cases. If the number is 1000, 
the disability weight for this disease will be 0.1 (14). 
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Time discounting 
 
Discounting benefits and costs over time is a common concept in the field of economics that can be applied to 
both health and non-health effects. The principle of discounting is based on the common observation that people 
prefer benefits now rather than in the future.  
The use of discount rates, or even differing discount rates, obviously has an impact on the burden estimates and 
may result in limited or no comparability among the generated DALYs and other studies. So far, the GBD 
estimates have been based on a three per cent time discount rate. However, several national and sub-national 
studies have not included any discount rate. Future GBD estimates will therefore be presented as both 
discounted and undiscounted estimates.  
Time discounting cannot be applied to the DALYs used in this study, for which both acute illness and sequelae 
are linked to the pathogen and long-term sequelae are projected to the present. Discounting can only be applied 
properly when modelling the full time-dependence of infection and sequelae. Only when the occurrence of 
sequelae can be determined in time (since infection) can the time between infection and occurrence of sequelae 
be discounted. Therefore, for the approach adopted in the base case analysis discounting will not be used. This 
may change when disease progression models are available for some infections included in the study − a 
necessity when modelling the impact of interventions on disease burden. The implication is that in this study 
future and present disability are weighted equally. 
Age weighting 
 
Integrating an age-weighting function into the DALY measure reflects the value given to life lived at different 
ages. This can be a subjective value but also an economically relevant value, reflecting the productivity of 
individuals of certain ages within society. Age weighting is highly debated and the exact quantitative 
implementation is controversial.  
The decision to include age-weighting in the first GBD study was made in order to best fit the human capital 
theory. This ensured that a value was placed not only on the “intangible costs” of suffering, pain and premature 
death, but also on the indirect potential loss of income of the individuals in question. In the past GBD estimates 
were presented both with and without age weighting (e.g. WHO GBD 2001 data).4
In the BCoDE project, the burden estimates should only include the intangible costs of reduced health − i.e. 
premature death and disability. Age weighting will therefore not be considered in the base case analysis. If there 
are compelling reasons for including age weighting at a later stage of the project (possibly to link to other studies) 
the modular modelling approach will allow the rapid implementation of any such extension.  
 
Data and data availability 
Time span 
 
Communicable diseases differ in their long-term dynamic behaviour and may display distinct time trends in 
incidence over the years. While for some communicable diseases incidences remain constant for long time 
 
                                                                    
4 http://www.who.int/healthinfo/global_burden_disease/estimates_regional_2001/en/ 
To estimate incidence and mortality, data collected over a three-year time period (2005-2007) will be used. 
When estimating incidence of infection the point of departure will be notification data from routine surveillance 
systems. For each disease an assessment will be made as to whether incidence data from this time period is 
representative of the disease epidemiology, or whether there are underlying time trends that should be taken 
into account. In the event of longer time trends a decision will be taken as to whether to expand the time 
period to include 10 years of surveillance data. If good population-based studies are available for other time 
periods they will be considered as well. 
Age weighting will not be applied in this study. 
Time discounting will not be applied in the base case estimates. 
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periods, for others the incidence decreases (increases) or oscillates over time. If there is a monotone decreasing 
(or increasing) time trend in incidence, long-term averages would overestimate (or underestimate) the disease 
burden, as shown in Figure 3. Therefore, to avoid the influence of long-term trends on estimates we will base 
our incidence estimates on data from a three-year time period (2005–2007). 
However, for infections with irregular (non-monotonic) time trends over one or several years, or for diseases that 
occur in incidental epidemics, a long-term average may be more representative of expected annual incidence. If 
a three-year time period is found to be too short to adequately represent typical incidences for a specific 
infectious disease, we will consider using a longer time period (e.g. a 10-year period). For infections taking the 
form of clearly defined outbreaks, the distribution of outbreak sizes will be considered in order to quantify 
expected numbers of cases and their variance. 
Figure 3. Assuming a downward time trend for an infection displaying symptoms in the same year 
(a) and for an infection where symptoms only occur after 10 years (b) 
  
- Blue rectangles represent the number of infections in the year of infection (exposure to an infection) 
- Green “cans” represent the number of cases with symptoms where these cases occur in the same year as 
the infection (a) or a few years later (b), as indicated by the dashed arrow 
- The long-term average (ø) is highlighted by a light-blue oval for incidence and a light-green oval for 
prevalence 
- The short-term average (ø) is represented by a blue oval for incidence and a khaki/green oval for 
prevalence. 
Number of fatal cases 
 
Mortality data, preferably obtained from national statistics institutes and EUROSTAT, will be compared in order to 
estimate the burden due to premature death, stratified by age and sex.  
One difficulty with this is that mortality is often not attributed to the underlying communicable disease that 
causes the condition leading to death. It is therefore necessary to estimate what fraction of the conditions 
registered as cause of death can be attributed to a communicable disease on the basis of cause-specific mortality. 
For some conditions and countries, estimates of attributable fractions are available. For others they have to be 
determined from outcome trees and information on disease progression and mortality rates.  
The number of fatal cases from conditions with various causes, such as liver cancer (caused by hepatitis B and C 
virus infection or alcohol abuse) or Guillain-Barré syndrome (caused by Campylobacter or respiratory infection), 
are difficult to distribute by underlying cause. We need to know how the cause of death is recorded at death 
The mortality data used will be stratified by age and sex, adjusted to correct for under- or over-reporting where 
applicable, and preferably obtained from national statistics institutes and EUROSTAT. The number of disease- 
and cause-specific fatalities from diseases with various causes is estimated either 1) by multiplying the absolute 
number of fatal cases obtained from disease-specific registers by an attributable fraction obtained from the 
literature, or 2) by modelling disease outcomes and mortality, taking into account the conditional dependency 
of the different health outcomes, as illustrated in the outcome tree. 
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registries in order to interpret mortality data and obtain an estimate of the number of deaths linked to a 
particular pathogen. In this project, the number of fatal cases caused by a specific communicable disease will be 
estimated by multiplying the absolute number of fatal cases from a condition, as obtained from disease-specific 
registers, with an attributable fraction for the disease obtained from the literature. Alternatively, we will estimate 
the disease-specific mortality by modelling the progression of disease through various outcomes starting from 
infection. This approach also takes into consideration the conditional dependency of the different health 
outcomes, as illustrated in the outcome tree. Ideally, both approaches should lead to comparable estimates for 
the number of fatal cases related to infection with a specific pathogen. If both estimates are available, one can 
validate the other.  
Number of non-fatal health outcomes 
 
Depending on the communicable disease, incidences have to be estimated for a varying number of non-fatal 
outcomes. If incidence of infections and an outcome tree are available these estimates can be obtained by using 
the incidence of one outcome (e.g. number of symptomatic infections) at the root of the tree and the 
(conditional) probability of progressing to the next stage or to recovery. However, data to estimate the 
progression might not be available for complete outcome trees and supplementary data will be required. In 
addition to routine surveillance data collected for notifiable diseases the results of population-based 
epidemiological studies are required. Comparing notification data with evidence from population-based studies 
will provide insight into the quality of surveillance and possible levels of under-reporting and under-
ascertainment. Incidence data should be differentiated according to surveillance level: non-consulting cases, 
cases where a PCP (primary care physician) was consulted and hospitalised cases (see Figure 4 below). This type 
of differentiation may help to ensure that the data is less biased by under-reporting, however it will seldom be 
complete. It is necessary to estimate the extent of under-reporting and of possible biases (from epidemiological 
studies) in the data. The degree of under-ascertainment may be available from community cohort studies or 
outbreak studies. The above implies that incidence of disease outcomes may be estimated from routine 
surveillance data, with correction for under-reporting and under-ascertainment, and by applying quantitative 
knowledge about disease progression. Alternatively, the incidence of disease outcomes has to be estimated from 
sources other than notification data (e.g. hospitalisation data together with information about attributable 
fractions), or information has to be taken from population-based studies. In a situation where the disease is in a 
steady state, or where infectious diseases develop within a short time span, these two approaches should lead to 
the same results. This makes it possible to validate estimates for some communicable diseases and their 
sequelae. 
In the BCoDE project we will use surveillance data for notifiable infectious diseases (in particular TESSy, which is 
based on national surveillance systems), primary care data (where available), hospitalisation data and mortality 
data, all widely collected in European countries on a regular basis. Additionally, we will gather data from disease-
specific databases such as cancer registries. Although collected regularly, these data sources are inconsistent and 
vary in quality depending on disease and country. Potential drawbacks are the definition used, the fact that 
nationwide coverage might not be given and the possibility that the collected data might only represent the more 
severe cases. Despite these drawbacks, the data sources are informative and do give indications of time trends 
and other related health problems. Nevertheless, for most of the communicable diseases under investigation 
these data sources are insufficient and only represent part of the iceberg. Corrections will be necessary for 
under-reporting. However, there is no single method applicable to all communicable diseases. The most suitable 
method for correcting under-reporting will have to be decided on the basis of each specific disease and country, 
depending on the evidence gathered and the data availability (of regularly collected and other sources). To this 
end, data other than notification data are needed and will be used where available. 
Many non-fatal health outcomes can be caused by several pathogens or by non-communicable diseases, e.g. 
liver cancer and Guillain-Barré syndrome. Incidences related to a particular pathogen will be estimated by 
multiplying the number of reported cases with an attributable fraction obtained from the literature and/or by 
modelling the steps through the outcome tree, starting from incidence of infection and taking into consideration 
the conditional dependency of different health outcomes.  
Incidence data for number of infections, sequelae and mortality will be stratified by age and sex, adjusted to 
correct for under- or over-reporting where applicable, and preferably obtained from national health institutes or 
ECDC (TESSy). The number of cases of disease- and cause-specific sequelae are estimated either by 
multiplying the absolute number of cases, as obtained from disease-specific registers, with an attributable 
fraction obtained from the literature; or by modelling disease progression and occurrence of outcomes taking 
into account the conditional dependency of the different health outcomes, as illustrated by the outcome tree. 
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Duration and severity of health states 
 
Durations of health states for chronic diseases are usually measured in years. Disability weights are then defined 
per life year lived with this disability. For infectious diseases with a short acute phase, this approach may not be 
appropriate. For short duration diseases disability weights can be determined per episode by focusing only on the 
phase of acute disease (period profile) or by focusing on a year in which an episode of acute illness is 
experienced (annual profile). Both methods have been tested and it appears that using the annual profile may 
overvalue disability weights. In the BCoDE project disability weights per episode (period profile) will be used 
where available and applicable.  
For conditions with less than one year’s duration the annual profile will be used for weighting. For conditions 
lasting more than one year the disability weights will be multiplied by the duration in years to obtain the total 
burden. Depending on the infection, health care systems also have an impact on the (conditional) probability of 
progressing to the next stage of care. Therefore, the duration of health states will be based on national 
estimates, if available. If national data is not available, estimates will be obtained from the literature. 
Under-reporting 
 
Introduction 
When estimating disease burden the under-reporting and under-ascertainment of data generate a degree of 
uncertainty. During a recent pilot study of the burden of infectious diseases in Europe, Van Lier et al suggested 
that the true burden of disease was not fully represented by raw, non-manipulated datasets owing to the 
probability of under-estimation for all diseases and countries (5). It would therefore appear to be crucial to 
identify areas of under-estimation in order to employ correction methods and determine the true burden of 
disease. 
In the past there has been some confusion over the meaning of the terms under-ascertainment and under-
reporting. In this study under-ascertainment is used to refer specifically to cases or exposure in the community 
which are not recorded by a notification or surveillance system due to the fact that healthcare advice is not 
sought. Under-reporting refers more specifically to cases where healthcare advice is sought but the infection 
status is misdiagnosed, misclassified, miscounted or the information summarised, meaning that full details are 
not passed on to national statistical bodies. In short, under-ascertainment occurs within the community and 
under-reporting occurs within institutes and involves physicians, hospitals, laboratories, governments and 
networks.  
The ‘iceberg’ analogy 
The surveillance pyramid or ‘iceberg’ metaphor (see Figure 4) illustrates the impact of infectious diseases on 
society and suggests patterns of health-seeking behaviour. More importantly, it indicates general levels of 
surveillance and data collection within the healthcare system, areas that are subject to varying rates of under-
reporting and under-ascertainment. These levels include the general population (defined as the total population, 
including hospitalised and otherwise institutionalised persons in which all exposure and cases occur); PCPs and 
hospitals (which represent a proportion of all exposure) and the mortality level (representing a proportion of 
those hospitalised and a smaller proportion of those exposed). As under-reporting and under-ascertainment rates 
vary at each level, a correction must be applied separately for each level. Therefore, it is important to separate 
these different levels in burden of disease studies.  
  
Correction for under- or over-reporting and under-ascertainment has to be evaluated specifically for each 
disease and country. Adjustments depend mainly on data availability and on disease-specific characteristics of 
diagnosis and reporting. 
The duration of health states is based on national estimates, where available. This will be compared with 
estimates extracted from the literature. If no national figures exist, estimates from the literature will be used. 
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Figure 4. Burden of infectious disease in society — the ‘iceberg’ 
 
Source: PPT adapted from a figure produced by the Health Protection Agency, UK (15).  
Available methods - general 
There are different ways in which to adjust data for under-reporting and under-ascertainment. All methods aim 
to estimate multiplication factors that relate reported data to complete and partially unreported data. In general, 
multiplication factors are age-dependent. The method used to estimate them depends on the specific disease, 
the type of data available and the reasons for under-reporting and under-ascertainment. 
Multiplication factors 
Multiplication factors can be applied to the reported number of cases of a particular disease in order to estimate 
the true number of cases.  
Multiplication factors are developed by comparing incidence or exposure in the general population (determined 
by community-based or serological studies) with the data on notified cases (including incidence of hospitalisation, 
laboratory-confirmed cases, PCP-confirmed cases and deaths attributable to the disease). Multiplication factors 
must be disease-specific (since under-reporting exists in varying degrees for different diseases); country-specific 
(owing to variations in disease exposure, healthcare systems, availability of treatment or cultural, social and 
technological differences); age-specific (since rates of under-reporting differ among age groups for many 
diseases) or possibly gender-specific. In some instances multiplication factors may even need to be strain-
specific. One example might be seasonal influenza where diverse seasonal strains will cause varying degrees of 
symptomatic disease and associated health-seeking behaviour. Thus, the community burden for strains causing 
milder symptoms and lower rates of healthcare-seeking behaviour will be under-represented to a greater extent. 
There are few community-based studies enabling the estimation of multiplication factors in such detail. In most 
cases we only have rough estimates of the ratio of reported to unreported cases.  
In a study by Mead, multiplication factors were used to correct for under-reporting or under-ascertainment at the 
community level in hospitalisation data and mortality data (16-17). Multiplication factors borrowed from previous 
studies were used to estimate true illness in the community, whereby the degree of under-ascertainment of 
illnesses caused by Salmonella and other non-bloody diarrheal pathogens was 38-fold and the degree of under-
reporting of illnesses caused by E. coli O157:H7 and other bloody diarrheal pathogens was 20-fold. For 
pathogens causing severe conditions the degree of under-reporting was 2-fold, since it was considered more 
likely that such cases would present to healthcare facilities. Hospitalisation data and mortality data were doubled 
to account for under-reporting, producing a lower figure than that applied to under-ascertained community data 
since it is believed that once in the healthcare system, there is a higher probability that cases will be reported.  
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In a second study by Van Damme et al. (18) a multiplication factor of six was applied to reported hepatitis B 
case data for all 30 EU and EEA/EFTA countries to calculate the ‘true’ incidence of hepatitis B exposure in the 
community. This was calculated by assuming a factor of two to correct for under-reporting and a factor of three 
to correct for asymptomatic cases, based on the knowledge that two-thirds of infections are asymptomatic.  
Using the same multiplication factors for different countries and populations does not take into consideration vital 
inter-country differences, such as whether a disease is notifiable, whether the reported data has already been 
adjusted, how good the data collection and reporting systems are and whether there are differences in 
diagnostic approach between countries. In conclusion, when applying multiplication factors, the differences 
between countries have to be assessed and taken into account so that multiplication factors can be based on 
country-specific evidence. Obviously, multiplication factors are disease-specific and depend strongly on the 
clinical presentation and severity of an infection and how it is distributed in the population. Furthermore, clinical 
symptoms are usually age-dependent and may often be different for men and women. Rational, evidence-based 
choices have to be made for the values of all multiplication factors. 
As a general rule, multiplication factors have to be separated into one factor describing under-ascertainment and 
one describing under-reporting. Both will be assumed to be age- and sex-dependent.  
Ways of estimating multiplication factors 
Statistical or dynamic models are used in almost all methods for estimating the extent of under-reporting and 
under-ascertainment. Statistical models are required to translate the results of telephone, postal or serological 
surveys into estimates of multiplication factors. In some studies, a modelling framework, rather than a statistical 
analysis, is used to translate clinical knowledge about the course of an infection and disease into a multiplication 
factor (e.g. a model relating the number of symptomatic cases to the total number of infections). Modelling 
frameworks may make use of reported prevalence, incidence or mortality data to calculate the expected 
incidence of specific outcomes. These can then be compared to the reported incidences to understand the 
magnitude of under-reporting and under-ascertainment. 
By way of example, the decision tree model approach has been used to estimate under-detected cases of rabies 
in Tanzania (19) and Trypanosoma brucei rhodesiense sleeping sickness cases in Uganda (20). It is therefore 
assumed that with some modification of the model parameters the quantitative framework could be applied to a 
range of other diseases. For the project in Uganda, a deterministic model was also developed to estimate the 
proportion of undetected cases that sought healthcare.  
Age-specific disease curves identify incidence of disease at a given age but can also identify ages for which there 
is significant under-reporting. Two studies that used this method also used regression as a secondary step (21-
22). Another example is a study by Majowicz et al (23), where the authors used Monte Carlo simulation to 
estimate the number of non-typhoidal Salmonella gastroenteritis cases in order to calculate the global burden of 
this disease.  
Some aspects of modelling (statistical analysis) will be clearly be vital for correcting under-estimation of disease 
burden. As this project progresses, it will be necessary to fully investigate existing and available models in order 
to decide whether they are suitable for the project, or relevant to the situation in Europe. It will also be 
necessary to discuss whether one disease-specific model would be appropriate for all European countries or 
whether country- or region-specific models would be more appropriate. 
Models already exist for predicting or estimating the community burden of various diseases in a number of 
different countries. The use of existing disease models could be advantageous in that it would avoid the need to 
develop new models — a process which is often complex and time-consuming. However, it may prove necessary 
to develop new models in order to give the best estimate of disease burden and correct for under-reporting and 
under-ascertainment. 
Capture-recapture methods and log linear models 
The capture-recapture method involves comparing data from various sources and registries and establishing 
whether cases have been captured from more than one data source. To do this it must be possible to link the 
data at the individual level. This technique has been used in combination with analytical techniques, including 
log-linear models and others, to correct for under-reporting. Capture-recapture studies have been performed in 
the context of infectious disease surveillance for tuberculosis, meningococcal diseases and others. 
Under-reporting of mortality can also be assessed by capture-recapture analysis. In a study of pertussis deaths in 
England (1994-1999), it was suggested that 46 deaths were attributable to pertussis but only 33 had been 
identified, classified correctly and reported to the relevant authorities (24). 
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Community-based studies 
The umbrella term “community-based studies” includes serological surveys and population-based telephone, 
internet or postal surveys. Community-based studies aim to measure the incidence of infection (symptomatic 
and/or asymptomatic) in the population and in this way quantify the proportion of infected persons that contact 
the healthcare system and are diagnosed. They therefore provide a basis for estimating the multiplication factors 
used for under-ascertainment. 
Population-based surveys 
Population-based surveys actively search for community disease incidence, usually within a randomly chosen 
sample of the population (cross-section) or a cohort followed over a given time period. Typically this involves 
identifying cases that fulfil a case definition (gastroenteritis, influenza-like illness) and performing studies, 
including microbial diagnostics and embedded case-control studies, to investigate the healthcare-seeking 
behaviour that such cases provoke. 
The community-based incidence described in such a study can be compared to that reported in notification 
systems, which should then give an idea of the magnitude of under-reporting and under-ascertainment. 
Population-based surveys are a useful way of gaining information on community-level under-reporting for those 
diseases that are self-limited or mild (e.g. gastrointestinal infections), and those that are asymptomatic and 
therefore do not prompt healthcare-seeking behaviour (some sexually transmitted infections (STIs), including 
gonorrhoea and Chlamydia). Population-based surveys can also be useful for estimating the under-reporting of 
infections diagnosed by physicians and in hospitals and laboratories. However, few population-based surveys are 
available because they are time-consuming and expensive.  
Examples of population-based surveys  
One type of population-based study is the cross-sectional telephone survey. This involves interviewing a 
randomly chosen sample of the total population to determine community opinions, habits, preferences and, in 
this instance, disease incidence. When investigating the occurrence of infections, syndrome information is usually 
requested. This involves determining whether an individual has experienced certain symptoms within a given 
time period, the severity of the symptoms, whether respondents sought healthcare and other information. In a 
recent retrospective cross-sectional telephone survey in Canada by Henson et al (25) the incidence of 
gastrointestinal disease was estimated. Other parameters, including hospital and physician visits, house calls, 
laboratory tests, medication and days of work missed, were useful for investigating the epidemiology of those 
diseases. The survey findings were first subjected to regression analysis and then modelling as a secondary step 
to estimate the monetary cost of burden.  
A similar study was conducted by Majowicz et al (26) in a single city in Canada and by Thomas et al (27) in three 
locations across Canada, both trying to estimate the burden of gastrointestinal disease. Other examples of cross-
sectional telephone surveys include a study that assessed the level of influenza vaccination coverage during two 
consecutive influenza seasons (2002/2003 and 2003/2004) in five European countries (28); a study which used 
computer-assisted telephone interviews to assess the lifetime and recent history of STIs and blood-borne viruses 
(BBV) in Australia (29) and studies of gastrointestinal diseases in USA (30) and Ireland/Northern Ireland (31). 
The postal questionnaire is similar to the telephone survey with correspondence being conducted via post. Again 
the questions are oriented towards a particular outcome whereby certain answers would class an individual as a 
case (perhaps even a possible, probable or definite case) or a non-case. An example of a prospective 
community-cohort study combined with a PCP-cohort study was used in the United Kingdom (32-33) and in the 
Netherlands (34-35) to estimate gastroenteritis incidence at the different layers of the surveillance pyramid. 
Initially a baseline survey of an invited (randomly chosen) cohort was carried out and then weekly cards sent to 
report on any gastrointestinal symptoms. If the subject was suffering from diarrhoea, stool samples were also 
obtained so that pathogens could be identified. Conducting prospective studies, targeting specific syndromes and 
following up with etiological studies and registration of outcomes are among the most viable methods for 
obtaining information on incidence numbers, etiology, multipliers and outcomes, although probably the most 
expensive. 
Another approach is the detailed analysis of large outbreaks and the use or non-use of medical care services in 
order to estimate the relationship between the levels in a pathogen-specific gastroenteritis reporting pyramid, for 
example. Combining such information with surveillance data gives an extrapolation of the number of cases in the 
general population. However, outbreak situations might not be comparable to sporadic cases in the population. 
Differences in susceptibilities of sub-populations, size of doses or other key areas can lead to differences in 
clinical symptoms and therefore in the likelihood of seeking medical care. Increased media coverage is a key 
factor, introducing biases in consultation behaviour during outbreak situations. 
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Face-to-face interviews, using a similar type of questionnaire to that described above, have also been used. 
Examples include a population-based study of Chlamydia in China (36) that used a computer-aided questionnaire 
and required participants to provide a urine sample, and a personal door-to-door survey of HIV and STIs in 
Slovenia (37). 
Another type of population-based study that can help to correct for under-reporting is described by Hsieh et al 
(38). A cohort of patients diagnosed as having urethritis, cervicitis or gonorrhoea in various health centres in 
Taiwan were interviewed and retested for gonorrhoea which demonstrated that 42% of positive gonorrhoea 
cases had not been reported to the National Gonorrhoea Notification Disease System (NGNDS). The main 
reasons given by clinicians for not reporting were that clinical samples had not been obtained, the clinicians were 
afraid to violate patient privacy and that they were unaware the disease was notifiable.  
Case-control studies in the population may also be used to estimate disease outcomes for specific pathogens. 
Case-control studies are performed for various purposes, such as determining risk factors or attributing illnesses 
to foods. They are usually conducted for laboratory-confirmed cases but can be applied to many of the 
approaches discussed above. Case-control studies are either prospective or retrospective and mostly rely on self-
reporting. Self-reported symptoms should ideally be confirmed by medical examinations to correct for over-
reporting. 
Population-based studies have the advantage of finding unreported or unascertained cases, but there are also 
some limitations, the most important being the possibility of bias, of which there are many types. Sampling bias 
due to non-random sampling of a population could be an issue and this would result in the study not being 
representative of the entire population. Certain ethnic, migrant, age, occupational or other groups may not be 
included in the study because they are unregistered, hard to reach, do not have access to a telephone (in the 
case of telephone surveys), or cannot read and write in the language of the study. There also may be a response 
bias since only certain types of people will agree to participate in the study, which again may lead to the sample 
not being representative of the entire population. Measurement bias may also be significant in terms of the case 
definition. If the case definition is too general or specific this could greatly increase or decrease the incidence of 
disease. In addition, interviewer interpretation of the interviewees’ answers may be biased or the respondents’ 
memory of disease occurrence may be distorted. Finally, such studies are time-consuming and costly and are 
therefore not feasible for many countries and diseases. 
Serological surveys 
Serological surveys are a tool for investigating the immune status of a population. In a population-based 
serological survey serum samples are collected from a representative sample of the population. These can then 
be tested for the presence of antibodies against a variety of infectious diseases. Depending on the disease and 
antibody tested, the samples may give information about past and recent exposure and possibly vaccine-induced 
immunity. Usually this information can then be stratified by age and sex. In the case of diseases for which 
serological data gives information about recent incidence of seroconversions, comparison with notification and 
hospitalisation data reveals what proportion of seroconversions were diagnosed and reported. Under-reporting 
and under-ascertainment can then be estimated by comparing the number of sero-positive cases and hence 
exposed individuals (sero-prevalence) with the number of reported cases (incidence/prevalence).  
Serological surveys have been conducted for a variety of infectious diseases, but only some of them are 
representative at the national level. Serological studies are a common epidemiological study method for 
estimating the prevalence of HIV and hepatitis B and C. For these diseases, acute infections are not easily 
detected and often remain asymptomatic. Similarly, they have a long chronic stage during which specific 
antibodies are present. Therefore measuring the population prevalence for these diseases gives the most reliable 
information about their epidemiology. Furthermore, serology can also act as a diagnostic tool for these infections. 
Numerous studies have also been carried out for other diseases including viral haemorrhagic fevers (VHF) and Q 
fever, for which the gold standard of diagnosis is also serology. However, as these diseases are considered rare 
in most countries, serological surveys of VHF and Q fever tend to be conducted by research groups as opposed 
to public health institutes and organisations. Moreover, as a result of limited resources, study sample sizes are 
often small and limited to certain geographical regions. 
Serological surveys have also been performed for diseases for which serology is a novel research approach. 
These include Salmonella, Campylobacter, Brucella, Cryptosporidium and syphilis. 
Serological surveys among animal populations as a measure of animal disease and as a proxy for human disease 
have been carried out for Salmonella, Brucella, Campylobacter, tuberculosis, influenza, Q fever and others. 
Studies are mainly conducted by research groups but some data are collected by surveillance networks and 
interest groups including the European Surveillance Network for Influenza in Pigs (ESNIP) 2, and Med-Vet-Net 
(Campylobacter, Salmonella). The Med-Vet-Net studies were in humans. 
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Finally, serological surveys of vaccine-preventable diseases are common and ongoing. The aim is mainly to 
assess the immune status of the population, including vaccine-induced immunity, and to identify regions of low 
herd immunity and potential outbreak threat. It is often difficult to differentiate between antibodies generated as 
a result of natural exposure and those resulting from vaccination. Therefore the epidemiological interpretation of 
serological data in terms of incidence of infection is sometimes difficult. 
An exception is pertussis, for which the impact of vaccination on antibody titres against pertussis toxin does not 
last long. Using information on the rate of decay of those antibodies after natural infection, the incidence of 
pertussis infections can be estimated from serological data. This was first done by de Melker, Versteegh et al. 
(39), resulting in an estimate for the proportion of pertussis infections notified per age group in the Netherlands. 
In a follow-up study, these methods were applied to age-stratified seroprevalence data from five European 
countries collected by the European Sero-Epidemiology Network (ESEN). The resulting incidence estimates show 
that there is a huge difference between the age distribution of notified cases and the age distribution of 
infections resulting in seroconversion. 
If good information is available on vaccination coverage over time in a population, the fraction of the population 
that has experienced natural infection can be estimated from the serological profile. Moreover, a comparison with 
notification data will give some information about possible under-reporting and age-biases in reporting.  
There are limitations to using serological surveys to determine under-reporting. Firstly, not all diseases have 
robust serological tests with reasonable sensitivity and specificity. Examples include pathogens with antibodies 
that cross-react with other pathogens such as Listeria, enterohemorragic E. coli and other bacteria. Thus, past 
serological surveys have been limited to a handful of diseases. For some diseases, extensive exposure may be 
needed to obtain a measurable serological response. For other diseases asymptomatic infections also result in 
sero-conversion. Interpretation of serological titres must therefore be disease and country-specific.  
A second limitation is that antibodies originating from natural exposure to a pathogen cannot always be 
distinguished from antibodies resulting from vaccination. Therefore, serological surveys of diseases for which 
there is routine vaccination within the community, including tuberculosis (BCG vaccine), measles, rubella, and 
other childhood vaccine-preventable diseases, may not easily be interpreted. Furthermore, for some diseases it is 
not possible to distinguish between past and recent infections, meaning that for these diseases sero-prevalence 
represents a cumulative lifetime incidence.  
Few sero-surveys have been carried out in representative population samples at the national level. Most 
serological surveys are limited to small samples of a population or to specific risk groups. Many serological 
studies have focused on measuring prevalence in high-risk groups (e.g. a serological survey of hepatitis C among 
intravenous drug-users). However, these groups would usually have a disproportionally high disease burden 
compared with the general population. Consequently, this data cannot be used to estimate disease burden for 
the population at large and supplementary information is needed concerning the size of risk groups and their 
contribution to overall transmission dynamics. In addition, different studies may use a variety of serological 
testing methods or different cut-offs to define positivity. This also limits comparability among studies.  
Routine serological testing takes place in various settings, for example to ensure the safety of blood products 
from blood donations. Nevertheless, this information, which could be useful for assessing the population 
prevalence of diseases such as HIV, hepatitis B and C, is not systematically analysed and published.  
There are European networks collecting and analysing serological surveillance data, including the European 
Commission-funded European Sero-Epidemiology Network 2 (ESEN2) which collects serological data on vaccine-
preventable diseases and the European Network for Diagnostics of "Imported" Viral Diseases (ENIVD), a network 
collecting serological surveillance data on rare, imported viral infections including viral haemorrhagic fever (VHF). 
In the ESEN network, methods have been developed to standardise serological data enabling the comparison of 
serological profiles in different populations. The results of these seroepidemiological studies have been published 
for a large number of vaccine-preventable diseases. 
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Available methods and their potential application in the BCoDE 
project 
General 
The BCoDE project relies heavily on notification data and other readily available data from surveillance systems. 
Data from routine surveillance sources needs to be adjusted to correct for under-reporting and under-
ascertainment. We distinguish at least three main types of data that represent the different levels of the 
surveillance pyramid and are obtained from different sources. These are: 
• Incidence of symptomatic infections (morbidity data): Incidence of illness in the community which 
includes both those that sought healthcare assistance through a PCP and those that did not.  
• Incidence of hospitalised cases of infection (morbidity data): Hospitalisation data should quantify the 
number of cases hospitalised and include additional details such as length of stay. Those hospitalised tend 
to be the more severe incidence cases.  
• Incidence of death due to the infection and its sequelae (mortality data): The number of deaths is usually 
quite well reported, but there is considerable misclassification of the causes of death. There is under-
ascertainment of secondary and tertiary causes of death. Moreover, details relating to conditions and 
possible sequelae that an individual died with (e.g. underlying causes) but not necessarily of (i.e. the 
primary cause of death) are frequently missing or not included in summaries. 
By identifying and correcting for under-reporting and under-ascertainment at each level within the pyramid, a 
more accurate and valid basis will be obtained for estimating disease burden. The BCoDE project will, in the first 
instance, use data that is publicly accessible or available via national public health institutes, adjusting for under-
reporting and under-ascertainment. The chosen correction methods will be disease-specific and the estimated 
multiplication factors will be country- and disease-specific, since the magnitude of under-reporting and under-
ascertainment within the surveillance pyramid varies greatly among diseases and countries, or even within one 
country for different periods or regions.  
Using current notification data and correcting for under-reporting and under-ascertainment will create a cross-
sectional view of morbidity and mortality incidence and burden in the society. Cross-sectional data gives a 
snapshot picture of acute illness, sequelae and death at the present time. In contrast, the longitudinal view 
considers disease and its outcomes over time and may therefore provide important information on (long-term) 
sequelae of infection. 
To obtain information about possible under-reporting or under-ascertainment of sequelae it will be necessary to 
utilise disease outcome trees. The steps required can only be performed after correction for under-reporting and 
under-ascertainment in the cross-sectional data. Briefly, the steps include: 
• Adjust notification data for under-reporting and under-ascertainment. 
• Enter the adjusted incidence data into the outcome tree model. Based on the transition probabilities given 
by the outcome tree, it is possible to estimate the proportion of incident cases that develop specific 
sequelae, recover or die from a particular complication. The model calculates the expected incidences of 
particular sequelae. Results are given in terms of incidence of sequelae and deaths. 
• Expected incidences of sequelae can then be compared to reported data on sequelae and sequelae-
attributable deaths. Differences between reported and expected outcomes will indicate under-reporting of 
sequelae, misclassification of sequelae or mortality and temporal changes in the epidemiology of the 
relevant disease.  
Stepwise application process 
A stepwise process for deciding how to deal with under-reporting and under-ascertainment and which correction 
method to use is described below. Ideally this process should be followed for each disease in each country to 
give country- and disease-specific correction methods. 
Cross-sectional comparison (see Figure 5 below) 
1. Gather information and evidence from national representatives. 
- Contact national health authorities: 
Their experiences could be useful for finding the most appropriate approach to correcting under-reporting 
and under-ascertainment. Furthermore, they may highlight the importance of the initial search for 
evidence if inter-country reported incidence data proves to be incomparable. It may be that a national 
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institute in one country publishes data already corrected for under-estimation, while an institute in 
another country only publishes non-manipulated data. It is vital to obtain this information from national 
health board representatives to be clear as to whether datasets are raw or manipulated. 
- Ask the national health authority representative if the country applies any form of correction method to 
manipulate raw data before publishing or reporting to international institutes to correct for under-
reporting and/or under-ascertainment. 
- If yes, more detailed information must be sought: methods used to correct; reasoning behind the choice 
of methods; to which diseases are the methods applied and at which institutional level is the correction 
factor applied to data? Institutional level 1 refers to the local collecting system (PCPs, hospitals and other 
health units), level 2 refers to the regional collecting department; level 3 refers to the national collecting 
and reporting department/office and level 4 refers to the international collecting and reporting 
department, which may include the World Health Organization (WHO) or ECDC’s TESSy. It is possible that 
there is some correction at each level and the extent of correction should therefore be determined for 
each level. 
 
- Contact National Surveillance Contact Points: 
As during data investigation the National Surveillance Contact Point can be contacted. Similar questions 
may be asked and any information obtained can be recorded and sent to the central group. 
2. Gather information and evidence from published literature to find past studies that correct for under-
reporting or under-ascertainment or suggest true incidence/burden from which multiplication factors can 
be derived to correct under-reporting and under-ascertainment. 
An extensive, systematic review of the literature should be conducted to find studies that have been done 
at both the regional and the international level for each country and each disease under investigation. 
Comparisons between the data sources are essential in order to ascertain the level of under-
reporting/under-ascertainment and establish correction methods. 
Study types likely to be most significant are: 
- Studies identifying areas of under-reporting/under-ascertainment of data for the relevant diseases and 
countries 
- Studies correcting for under-reporting/under-ascertainment for the relevant diseases and countries 
- Community-based studies (e.g. serological surveys or community-based telephone surveys) provide 
information on the background level of exposure or infection and could indicate the magnitude of under-
reporting/under-ascertainment. Multiplication factors can also be determined from this information in 
order to re-calculate reported data incidences for other datasets.  
- Outbreak investigation studies: These studies are useful as an additional measure of incidence since they 
involve active surveillance. However, outbreak studies must be treated with caution since during an 
outbreak physicians and hospitals feel the need to report more and have more samples laboratory tested. 
Similarly, the public become more aware through media coverage and people are more likely to seek 
healthcare.  
- Case-control and cohort studies: Useful for gathering information on development of sequelae following 
infection. Such studies may give more precise information about the rate and timing of sequelae 
development. 
- Modelling: Studies that use modelling frameworks may take into account the dynamic aspects of 
transmission, the indirect effects of intervention and other outcomes resulting from the communicable 
nature of infectious diseases. Models can also be used to reconcile conflicting evidence or assess the 
strength of different data sources systematically. However, designing consistent, evidence-based models 
is time-consuming. 
- Capture-recapture: This methodology can be used to estimate the completeness of registries and 
surveillance data. In particular, a capture-recapture study provides information about the proportion of 
cases not registered in any of the analysed data sources. In order to conduct a capture-recapture study 
there must be at least three largely independent data sources available for which data can be linked at 
the individual record level.  
- Multiplication factors: Publications that have previously estimated multiplication factors for specific 
diseases to calculate corrected incidences from reported data will be useful as a guide to the magnitude 
of such factors.  
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3. Compare incidences, as estimated from notification data and other registries, with information from 
specific studies found in step 2 for cases of disease in the community, hospitalised cases and deaths. 
4. Derive (age-dependent) multiplication factors for the three levels of reporting (notification, hospitalisation 
and mortality) and apply the multiplication factors to correct for under-reporting/under-ascertainment to 
obtain adjusted incidences. 
- If multiplication factors cannot be determined for the specific disease or country: 
- Review published literature to find past studies that correct for under-reporting/under-ascertainment 
using models or frameworks and assess their applicability to the current study. 
- Review published literature to find past studies that correct for under-reporting/under-ascertainment 
using any other method and assess applicability to the current study. 
- If a disease-specific or country-specific method cannot be found, a multiplication factor can be taken from 
elsewhere (a similar disease group or healthcare system) and superimposed for use in this situation. 
- If no applicable method of information is available, set all multiplication factors to 1. 
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Figure 5.  Flowchart for cross-sectional under-reporting 
 
Longitudinal comparison (applicable for data on sequelae) (see Figure 6 below) 
• Enter the adjusted incidence data (as per Figure 5) into the outcome tree model in order to estimate the 
expected incidence of sequelae and the mortality attributable to particular sequelae. 
• Compare expected incidences of sequelae, as determined from the outcome tree, with reported data on 
sequelae and sequelae-attributable deaths. 
• Based on this comparison, derive multiplication factors to correct for under-ascertainment of sequelae, 
associated morbidity and deaths. 
- Apply multiplication factors to correct for under-reporting and under-ascertainment. 
The observed differences between reported and expected outcomes will provide information on under-
reporting and under-ascertainment and possibly validate the consistency of the outcome tree modelling 
framework. 
  
Gather information from  
national representatives 
Is raw data manipulated to  
correct for under-
reporting/ascertainment? 
Gather information from  
published literature 
Compare notification data with 
data from specific studies. 
 
Derive age-dependent multiplication 
factors and apply. 
• Which methods? 
• All or some diseases? 
• Are correction factors age- or disease-
specific? - 
• Institutional level of correction factor? 
If factors cannot be derived for 
a specific disease/country: 
• Review literature for studies correcting 
under-reporting using models or other 
methods 
• If disease or country-specific studies 
are unavailable, borrow a multiplication 
factor and superimpose 
• If no method available, set all 
multiplication factors to 1. 
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Figure 6. Flowchart for longitudinal under-reporting (sequelae data) 
 
Modelling the burden of a particular pathogen 
Based on the defined outcome tree of a particular pathogen, a search is done for incidence data on all health 
states defined in the outcome tree.  
If available raw incidence data (morbidity and mortality) is collected for each health state for a three-year period. 
These three years of crude incidence data are used as input for our model. Based on this period, a crude annual 
mean incidence can be estimated, stratified by age and sex. Where necessary these incidences have to be 
corrected by a factor α  to correct for under-reporting, and by a factor β to correct for under-ascertainment. Both 
factors may be age-dependent and are specific to disease outcomes. These multiplication factors have to be 
obtained from the literature. For health outcomes with multiple sources the absolute number of cases, as 
obtained from disease-specific registers, will be multiplied by an attributable fraction δ obtained from the 
literature. For sequelae, but also for other health outcomes where no raw incidence data is available, we will 
estimate the number of cases by modelling the probability of occurrence of outcomes, taking into consideration 
the conditional dependency of the different health outcomes, as illustrated in the outcome tree.  
The disease burden is calculated from the number of notified cases as follows. Let n (a) be the number of 
notified cases at age a of a specific communicable disease with health outcomes i =1,…,k. Let 1/σ (a) be the 
proportion of cases in the community that are notified. The factor σ (a) is a product of factors α and β as 
defined above. Let pi (a) be the probability of developing outcome i  for an individual infected at age a (possibly 
after transition through a chain of subsequent outcomes, i.e. pi are not necessarily independent). Then σ (a)n (a) 
is the number of all infections in the community at age a and σ (a)n (a)pi  (a) is the number of cases of outcome 
i related to infections at age a. Let μi (a) be the probability that death occurs as a consequence of disease 
outcome i if infected at age a. Then di (a)= σ (a)n (a) pi (a) μi (a) is the number of deaths due to disease 
outcome i. The pi  (a) and μi  (a) are parameters that have to be estimated from disease progression studies. The 
multiplication factor σ(a) may be derived from various types of information including proportion of symptomatic 
cases, rate of diagnosis and notification rates. We can now integrate the outcome tree approach with the original 
DALY computation, as outlined on page 17. 
Now we have ni (a)= σ (a) n (a)pi  (a) as the number of cases at age a of health states i =1,...,k, where k is the 
number of different health outcomes resulting from the disease and di  (a), as defined above. Now as before, if E 
(a) is the remaining life expectancy at age a, and amax the maximum age, then 
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Enter adjusted incidence data into the outcome tree model to estimate the 
expected incidence of sequelae and mortality attributable to a particular 
sequela/disease outcome.
Compare expected incidences of sequelae from the outcome tree with 
reported sequelae data and sequelae-attributable deaths.
Derive a multiplication factor to correct for under-reporting of sequelae-
associated illness and deaths. This describes the gap between reported and 
expected outcomes and estimates the magnitude of under-reporting/under-
ascertainment for sequelae data.
Modelling and result presentation.
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The YLD is calculated as the product of the illness duration and the disability weight of a specific disease 
outcome, accumulated over the number of cases of all health outcomes. By denoting the duration of health 
outcome i as Di and its disability weight as wi, we obtain  
ii
a
a
k
i
iii
a
a
k
i
i wDapanawDanYLD )()()()(
maxmax
0 10 1
∑∑∑∑
= == =
== σ  
E(a) and Di have time as a unit, all other quantities are dimensionless numbers. Age is discretised into (amax +1) 
yearly age classes.  
By adding YLL and YLD we obtain DALYs (Disability-Adjusted Life Years) for pathogen i.  
Software used for burden calculation 
The disease burden models will be calculated in Microsoft Excel using @Risk, an add-in to Microsoft Excel that  
samples from probability distributions to obtain parameter values. Any uncertain parameter value in one of the 
Excel spreadsheet calculations can be replaced with an appropriated @Risk probability distribution function (e.g. 
Normal, Exponential, Uniform, etc.). The @Risk probability distribution function represents a range of possible 
values for a cell instead of limiting it to one value. Once all uncertain values have been replaced by appropriated 
@Risk functions and the output values defined, simulations can be run. @RISK recalculates the Excel 
spreadsheet model thousands of times, each time sampling random values from the @RISK functions entered, 
placing them in the model and recording the outcome. The simulations result in a sample of outcomes from a 
distribution of possible outcomes. In addition to expected outcomes, we therefore also obtain distributional 
properties of the outcome, such as the variance.  
The application of more advanced software will be explored to incorporate temporal variation in incidence. 
Modelling uncertainty 
The data necessary for the quantitative estimates of disease burden are often limited and/or absent, resulting in 
a degree of uncertainty.  
As a general rule, total uncertainty can be broken down into variability and uncertainty (Vose 2001). Variability is  
defined as the ‘inherent heterogeneity of a system’ (e.g. variations in the length of hospital stay for different 
patients). Uncertainty is usually defined as ‘a lack of perfect knowledge about a factor in the model that 
represents the system’ (more data, or better data would reduce uncertainty). 
A further distinction of uncertainty would be:  
• Statistical uncertainty due to small sample sizes 
• Systematic uncertainty, due to the quality of data which are not fully representative of the country and/or 
disease under investigation 
• Uncertainty due to lack of data. 
For base case estimates, in our model we have chosen to use only point estimates of variable parameters. The 
impact of variability can be assessed during a second stage of the analysis using sensitivity analysis. 
However, uncertainty will be explicitly modelled by incorporating probability distributions for uncertain 
parameters. These parameters will then be sampled from their probability distributions using Monte Carlo 
simulation to estimate predictive intervals.  
Systematic uncertainty and uncertainty due to lack of data are best presented through scenario analysis, as will 
be the case in this project. In a scenario analysis only one parameter will be changed at a time. 
Model outcome 
The outcomes of the model are disease burden estimates or Disability-Adjusted Life Years (DALYs) per year 
associated with a particular infectious agent and related sequelae for a particular country. Data are presented in 
both aggregated form (DALYs per year) and in disaggregated form (YLD per year and YLL per year), from a 
societal perspective (DALYs/YLL/YLD per year per country and per 100 000 population per country) and from an 
individual perspective (DALYs/YLL/YLD per year per individual infected case). Where relevant in order to assess 
intervention impact, YLD and YLL will be analysed for major sequelae.  
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Where possible, the estimates obtained will be compared with estimates derived from other studies. This mainly 
relates to the GBD study conducted by WHO. 
Results presentation 
 
The data necessary for quantitative estimates of disease burden are often limited and/or absent, resulting in a 
certain degree of uncertainty that will be presented in the results. 
Strengths and limitations 
Disease definition 
Disease definition is not always the same throughout Europe and this can lead to potential pitfalls when 
estimating disease burden. 
Incidence data 
When making the calculation the non-availability of incidence data, attributable fractions or conditional 
probabilities are potential limitations which, in some cases, might lead to the exclusion of a health outcome from 
the outcome tree for a selected pathogen. As a consequence the true disease burden may be underestimated for 
some of the pathogens selected. 
Although the aim is to conduct disease burden calculations of the selected pathogens for all EU Member States 
and EEA/EFTA countries, non-availability of incidence data or poor data quality are potential reasons for 
excluding some of the selected pathogens in particular countries. 
Age-specific data 
The non-availability or poor data quality of age-specific data for both fatal outcomes and chronic health states 
will increase the uncertainty of the average disease burden estimate. 
Duration of health states 
For some health states information on duration might be limited, increasing the uncertainty of the disease 
burden estimate.  
Time period 
The aim of the BCoDE project is to obtain a disease burden estimate representing the years 2005-2007. However, 
the data available from these years might not always be complete or representative of the epidemiology for a 
disease. We will therefore also make use of community-cohort studies conducted in earlier years. However, 
factors such as demographic change, behavioural change in the population and the introduction of medical 
treatments might have had an impact on the dynamic of an infectious pathogen over time and the results of 
such studies should therefore be interpreted with care. 
Incidental outbreaks of communicable diseases during the period under consideration lead to an overestimation 
(underestimation) of the disease burden if not noted and corrected. 
Under-reporting/under-ascertainment 
For most of the selected pathogens, some corrections will have to be made for under-reporting. However, these 
are only estimations of the true burden in the community and should therefore be interpreted with care.  
Steady-state assumption 
Medical interventions and therapies, demographic changes, climate change and other environmental and social 
changes have influenced and continue to influence the epidemiology of infectious diseases. These factors 
determine the transmission dynamics of infectious diseases and therefore influence the time trends of incidence 
and prevalence. Assuming a steady state limits the ability of the modelling approach to project disease burden 
into the future.  
The methodological approach described in the current protocol estimates the disease burden in a situation where 
the above factors are assumed to be unchanging over a long period of time (known as the steady state 
Mean estimates will be presented along with the associated statistical uncertainty. Scenario analysis is used to 
represent systematic uncertainty or uncertainty due to lack of data. 
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assumption). When projecting estimates into the future or assessing the impact of interventions in the past, 
temporal changes in environment and demography should be taken into account. At a later stage we therefore 
plan to use mathematical methods to model the potential dynamics of infectious agents over time.  
Antibiotic resistance 
Information on the incidence of infections with resistant pathogen strains is limited. For most pathogens, 
information on resistant strains is mainly collected in hospitals and cannot be extrapolated to the community. In 
principle, burden could be estimated by assessing the impact of resistance on various parts of the outcome tree. 
An infection with a resistant strain may have different transition probabilities and durations of sequelae 
compared to sensitive strains. However, infections with resistant strains are often concentrated in populations 
with other underlying conditions or immuno-compromised patients. Using our methodology it will be possible to 
conduct scenario analysis to assess the likely impact of resistance on disease burden.  
Comparability with GDB estimates 
Estimates derived with the methods outlined in this document will be comparable with GBD estimates to a 
certain extent. In particular, they will be comparable to estimates computed without discounting and age 
weighting for those diseases or groups of diseases that are included in both studies. Our estimates will differ 
from GBD estimates in that they will attribute certain sequelae to infectious causes.  
A question for comparison will be whether total burden estimates derived with our methods are higher or lower 
than GBD estimates, or whether our methods only lead to a different distribution of burden across disease 
classes. 
Next steps 
Using the methods described in this document disease burden estimates will be obtained that enable the impact 
of communicable diseases on population health to be compared between communicable diseases and with other 
non-communicable diseases and conditions. These comparisons can be made at the national level and between 
countries. Estimates of the burden of communicable diseases provide a basis for prioritising health policy and 
research funds.  
This protocol represents a first step towards delineating a concise description of the methodology used to 
estimate the burden of communicable diseases. As each step is being reviewed during the ongoing test phase of 
Work Package 2, the protocol will be updated to reflect experience with the practical implementation. 
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Annex 1. Diseases (pathogens and 
syndromes) 
Respiratory tract infections   Nosocomial infections (healthcare-associated 
infections) 
Seasonal influenza  Urinary tract infections (URI) 
Legionellosis  Surgical site infections (SSI) 
Tuberculosis Lower respiratory tract infections (LRTI)  
STI, including HIV and blood-borne viruses  Blood stream infections (BSI) 
Chlamydia Gastro-intestinal Infections (GII)  
Clostridium difficile 
Gonococcal infections Skin and soft tissue infections (SST) 
Hepatitis B Diseases as a consequence of infection 
Hepatitis C Cervical cancer (due to HPV) 
HIV  Gastric cancer (due to H. pylori) 
Syphilis End stage liver diseases (due to HBV and HCV) 
Food-and water-borne diseases  Primary liver cancer (due to HBV and HCV) 
Campylobacteriosis  
Cryptosporidiosis  
Infection with VTEC/STEC  
Giardiasis  
Hepatitis A  
Listeriosis  
Salmonellosis  
Shigellosis  
Toxoplasmosis  
Variant Creutzfeldt-Jakob disease  
Emerging and vector- borne diseases  
Q fever   
Tick-borne encephalitis   
Vaccine-preventable diseases  
Diphtheria  
Invasive Haemophilus influenza disease  
Invasive pneumococcal infections  
Measles  
Invasive meningococcal disease  
Mumps  
Pertussis  
Poliomyelitis  
Rabies  
Rubella  
Tetanus  
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Annex 2. Criteria used when selecting 
pathogens/diseases 
The master list is based on the objectives set out in the BCoDE Call for Proposal and includes: 
• Forty-nine communicable diseases and special health issues specified under Decision 2119/98/EC with 
amendments.  
• Other diseases and conditions which may result from infections, including infection-associated cancers. 
Based on a strong recommendation by the experts assembled at the BCoDE expert workshop in March 2010, 
the following conditions will be included in this category: end-stage liver disease or primary liver cancer 
related to hepatitis B virus (HBV), or hepatitis C virus (HCV) infection; cervical cancer related to human 
papilloma virus infection and gastric cancer related to Helicobacter pylori infection. 
• Other conditions were added following discussions with ECDC Disease-Specific Programmes (DSP) and 
include diseases such as leishmaniasis, Lyme disease, tick-borne encephalitis and viral haemorrhagic fevers 
(including Crimean-Congo haemorrhagic fever, diseases caused by hantaviruses, dengue, Rift Valley fever, 
diseases caused by the Marburg filovirus and chikungunya). 
Exclusion criteria: 
1. Expert consensus (based on expert consideration of published evidence) that the burden of a disease/special 
health issue is negligible, mostly due to very low incidence, defined as equal to or lower than 1/100 000 per 
year. 
2. Extreme methodological and practical difficulties foreseen in estimating the burden due to: 
- Lack of data and very low probability of data generation over the next five years 
- Serious methodological difficulties foreseen, for example in defining a disease and/or special health 
condition 
- Lack of disability weights for the most important health states of outcome trees, and absence of similar 
alternatives. 
Exemptions: 
If Criterion 1 for exclusion is met but: 
- the negligible burden is believed to be low due to vaccination programmes with high coverage, or 
- there is an outbreak potential based on history or theoretical considerations, 
then the disease/special health issue will be kept on the final list and an attempt made to estimate the burden in 
the absence of intervention (e.g. by using the prevented fraction estimates in the case of interventions and 
mathematical modelling in the case of outbreak potential). 
Process for defining the final list: 
• The master list will be reviewed by the ad hoc working group of the ECDC Advisory Forum. 
• Decisions will be based on a simple majority of responses from the group. 
• The working group will start by considering the methodological issues (Criterion 2 above, Column A in the 
example table below). If the majority of responses relating to the feasibility of burden estimation is negative, 
the disease/health issue will be dropped from the list. 
• The resulting shortlist will be assessed against the incidence (Criterion B: Above very low relative incidence 
i.e. ≥1/100 000 per year). Diseases that score a majority of “No” answers under Criterion B need to have a 
majority of “Yes” under Criterion C (Outbreak potential) or D (Vaccine-preventable with widely used vaccine) 
in order to be kept on the list.  
• The final list will then be discussed with the Chief Scientist of ECDC and the management team of the 
project consortium. 
Where necessary, experts can add or remove other diseases, by producing thorough justification which must be 
approved by the Chief Scientist of ECDC. 
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Table 2. Decision tool to facilitate selection of diseases/health conditions 
Diseases/health 
issues 
Criterion A Criterion B Criterion C Criterion D 
Respiratory tract 
infections 
Feasibility based on data 
availability or 
methodological issues  
Y/N 
Above very low relative 
incidence (i.e. 
≥1/100,000 per year) 
Y/N 
Outbreak potential? 
Y/N 
Vaccine-preventable 
with widely used 
vaccine? 
Y/N 
1 Seasonal influenza     
2 Avian influenza     
3 Legionellosis     
4 Tuberculosis     
5 etc.     
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Annex 3. Comparison of pathogen-based 
DALY approach with incident case modelling 
approach to generate DALYs 
Table 3. Comparison of pathogen-based DALY methodology and incident case modelling approach 
 Extent of 
complexity 
and data 
requirement 
Inclusion 
of burden 
due to 
long-term 
sequelae 
Population 
base 
Consideration 
of time-to-
event 
Consideration 
of competing 
risks and 
background 
mortality 
Compatibility 
of estimate 
with data 
from GBD 
project 
Applicability 
of approach 
Pathogen-
based 
DALY 
approach 
+++ Yes Cross-
sectional, 
multi-cohort 
No No ? Prioritisation 
+ 
comparison 
Incident 
cases 
modelling 
approach* 
++++ Yes Longitudinal, 
multi- or 
single-
cohort 
Yes Yes No (see 
time-to-
event and 
competing 
event) 
Prioritisation 
+ 
comparison 
+ 
forecasting 
+ economic 
evaluation 
* Suitable for both DALY and QALY calculations. This approach focuses exclusively on incident disease cases. The burden of 
disease is derived by modelling the fate of these cases over their remaining lifetime and comparing the modelled life-
expectancy or quality-adjusted life-expectancy with the respective expectancies of a standard population without the disease. 
Longitudinal, single- or multi-cohort consideration (closed or open cohort) requires a valid natural history model. Modelling 
outcome: incremental QALY or DALY. 
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